EPO pharma case law trends 2025: Antibodies and biologics By Dr Rose Hughes on Monday, November 17, 2025 antibodies antibody inventions biologics epo EPO Boards of Appeal PatKat Rose Hughes +
Takeda v Roche: "Is it plausible? Is it true?" By Dr Rose Hughes on Thursday, August 01, 2019 biologics biosimilars Entyvio insufficiency monoclonal antibody mr justice birss patents plausibility Roche Second medical use takeda Vedolizumab Warner-Lambert +
SPCs based on a second marketing authorisation - the fight continues (Novartis C-354/19) By Dr Rose Hughes on Friday, June 28, 2019 article 3(c) biologics canakinumab CJEU Ilaris monocolonal antibody Novartis patents pharmaceutical industry Second medical use SPC SPC regulation Supplementary Protection Certificate +
Roche shields itself from a UK Arrow: Pfizer v Roche By Dr Rose Hughes on Thursday, June 27, 2019 arrow declaration Arvastin bevacizumab biologics biosimilars monoclonal antibody mr justice birss patents pfizer Roche SPC +
Fordham 27 (Report 9): Biologics and Biosimilars By Annsley Merelle Ward on Sunday, April 28, 2019 #IPKat AmeriKat amgen v sanofi biologic launch biologics biosimilars BPCIA event report fordham 2019 humira injunctions launch psk9 +
Shall we dance? Regulatory approval, trade secrets and the transatlantic biosimilars patent wars By Annsley Merelle Ward on Sunday, March 12, 2017 AmeriKat biologics biosimilars BPCIA EFPIA fujifilm marketing authorisation patent litigation patent strategy regulatory approval regulatory data trade secrets us patent litigation +
The Evolution of U.S. Law and the Bio-Pharmaceutical Industry By Mike Mireles on Wednesday, April 06, 2016 America Invents Act biologics biosimilars biotechnology Defend Trade Secrets Act pharmaceutical industry trade secrets +